Annovis Bio, Inc. (ANVS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Annovis Bio reported revenue of $0. Net income was -$28.9M, or -$1.40 per diluted share. Operating activities generated -$25.6M of cash. At fiscal year end, Annovis Bio held $21.1M in total assets against $4.2M in total liabilities, including $19.5M of cash and equivalents.
Open the full interactive Annovis Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Annovis Bio Key Stats
| Share Price | $1.06 |
|---|---|
| Market Cap | $39.8M |
| 52-Week Range | $1.04 – $5.10 |
| Shares Outstanding | 37.5 million (basic, 2026 Q2) |
Annovis Bio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$6.6M | -$14.5M | -$25.5M | -$45.0M | -$26.7M | -$29.7M |
| Pre-Tax Income | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Diluted EPS | -$0.87 | -$1.90 | -$3.10 | -$6.23 | -$2.31 | -$1.40 |
Annovis Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.3M | -$9.8M | -$17.6M | -$14.8M |
| Diluted EPS | -$0.37 | -$0.48 | -$0.63 | -$0.40 |
Annovis Bio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.1M | $45.7M | $28.4M | $5.8M | $10.6M | $19.5M |
| Current Assets | $8.1M | $46.0M | $36.0M | $10.2M | — | — |
| Total Assets | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M |
| Current Liabilities | $578,380 | $1.5M | $7.7M | $4.3M | $3.9M | $3.6M |
| Total Liabilities | $578,380 | $1.5M | $7.7M | $18.0M | $4.6M | $4.2M |
| Shareholders' Equity | $7.5M | $44.5M | $28.3M | -$7.8M | $9.3M | $16.9M |
Annovis Bio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M |
| Cash From Financing | $12.0M | $46.7M | $4,613 | $17.3M | $26.7M | $34.6M |
Figures from Annovis Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Annovis Bio financials page for every line item.
Annovis Bio Company Profile
| Ticker | ANVS |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Malvern, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001477845 |
Frequently Asked Questions
What was Annovis Bio's revenue in fiscal 2025?
Annovis Bio (ANVS) reported revenue of $0 for fiscal 2025.
What is Annovis Bio's annual revenue history?
Annovis Bio's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Annovis Bio's net income in fiscal 2025?
Annovis Bio reported net income of -$28.9M for fiscal 2025.
What was Annovis Bio's earnings per share (EPS) in fiscal 2025?
Annovis Bio's diluted EPS was -$1.40 for fiscal 2025 (adjusted for any later stock splits).
What was Annovis Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Annovis Bio reported revenue of $0.
How many shares of Annovis Bio are outstanding?
Annovis Bio reported a weighted average of 37.5 million basic shares outstanding in 2026 Q2.
What is Annovis Bio's market cap?
Based on its latest closing price, Annovis Bio (ANVS) has a market capitalization of about $39.8M.
When does Annovis Bio's fiscal year end?
Annovis Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Annovis Bio headquartered?
Annovis Bio lists its business address in Malvern, Pennsylvania in its SEC filings.